PFM Health Sciences’s Novavax NVAX Stock Holding History

PFM Health Sciences’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-81,000	Closed	-$14.7M	–	95
2021 Q1	$14.7M	Sell	81,000 -69,000	-46%	-$13.7M	0.45%	56
2020 Q4	$16.7M	Buy	+150,000	New	+$15.9M	0.59%	56

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PFM Health Sciences's NVAX Position: Q1 2022 in Review

PFM Health Sciences sold out of Novavax (NVAX) in Q1 2022, closing a stake of 88,663 shares — an estimated $12.7M sold.

PFM Health Sciences first reported a position in NVAX in Q4 2020 and held it in 5 quarters. The position peaked at $40.9M in Q3 2021. 382 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

PFM Health Sciences reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
PFM Health Sciences sold 88,663 Novavax shares in Q1 2022, an estimated $12.7M.
PFM Health Sciences first reported a position in Novavax in Q4 2020 and held it in 5 quarters.
PFM Health Sciences's Novavax position peaked at $40.9M in Q3 2021.
382 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.